Abstract
Transgenic mice models for Alzheimers disease (AD) are essential to the understanding of disease pathophysiology, develop robust behavioral models and predict outcomes from pharmacological interventions. In the last 10 years, numerous mice models have been developed particularly focusing on the amyloid precursor protein-processing pathway and Tau pathology since brain amyloid deposits and Tau tangles are some of the primary neuropathological consequences of AD. Current views on the amyloid hypothesis and mice models relating to the role of soluble Aβ oligomers and intracellular Aβ in AD pathophysiology will be reviewed. Several novel transgenic mice models that have recently been developed and their potential impact on understanding disease pathogenesis will also be summarized.
Keywords: Alzheimer's, transgenic, APP, Tau, Abeta, amyloid, oligomer, intraneuronal, neurodegeneration, mutation
Current Topics in Medicinal Chemistry
Title: Genetically Modified Mice Models for Alzheimers Disease
Volume: 6 Issue: 6
Author(s): Sethu Sankaranarayanan
Affiliation:
Keywords: Alzheimer's, transgenic, APP, Tau, Abeta, amyloid, oligomer, intraneuronal, neurodegeneration, mutation
Abstract: Transgenic mice models for Alzheimers disease (AD) are essential to the understanding of disease pathophysiology, develop robust behavioral models and predict outcomes from pharmacological interventions. In the last 10 years, numerous mice models have been developed particularly focusing on the amyloid precursor protein-processing pathway and Tau pathology since brain amyloid deposits and Tau tangles are some of the primary neuropathological consequences of AD. Current views on the amyloid hypothesis and mice models relating to the role of soluble Aβ oligomers and intracellular Aβ in AD pathophysiology will be reviewed. Several novel transgenic mice models that have recently been developed and their potential impact on understanding disease pathogenesis will also be summarized.
Export Options
About this article
Cite this article as:
Sankaranarayanan Sethu, Genetically Modified Mice Models for Alzheimers Disease, Current Topics in Medicinal Chemistry 2006; 6 (6) . https://dx.doi.org/10.2174/156802606776743020
DOI https://dx.doi.org/10.2174/156802606776743020 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Medicinal Chemistry Advancement in Life-Threatening Diseases
The current issue will highlight concise reports that specify ground-breaking insights, including the novel discovery of drug targets and their action mechanism or drugs of novel classes. These are projected to encourage medicinal chemistry future efforts to address the most challenging medical needs. The current issue highlights further efforts to ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
QSAR Applications During Last Decade on Inhibitors of Acetylcholinesterase in Alzheimer’s Disease
Mini-Reviews in Medicinal Chemistry Cell Signaling Mechanisms by which Geniposide Regulates Insulin- Degrading Enzyme Expression in Primary Cortical Neurons
CNS & Neurological Disorders - Drug Targets Immune-mediated Cerebellar Ataxias: Practical Guidelines and Therapeutic Challenges
Current Neuropharmacology Pharmacogenetics in Psychiatry - A Useful Clinical Tool or Wishful Thinking for the Future?
Current Pharmaceutical Design Calpain-1 and Calpain-2 in the Brain: Dr. Jekill and Mr Hyde?
Current Neuropharmacology Review of Recent Patents in the Area of Intelligent, Adaptive, Wireless and GPS Enabled HVAC Control Devices
Recent Patents on Engineering Insulin Resistance and Alzheimers Disease: Molecular Links & Clinical Implications
Current Alzheimer Research The Tachykinergic System as Avenues for Drug Intervention
Recent Patents on CNS Drug Discovery (Discontinued) Effects of Different Types of Physical Exercise on the Perceived Quality of Life in Active Elderly
CNS & Neurological Disorders - Drug Targets α7 Nicotinic Receptor Agonists as Potential Therapeutic Drugs for Schizophrenia
Current Medicinal Chemistry - Central Nervous System Agents Lights and Shadows on Monoamine Oxidase Inhibition in Neuroprotective Pharmacological Therapies
Current Topics in Medicinal Chemistry Physical and Mechanical Therapies for Lower Limb Problems in Juvenile Idiopathic Arthritis: A Systematic Review (Protocol)
Applied Clinical Research, Clinical Trials and Regulatory Affairs Animal Models in Neurology: Drawbacks and Opportunities
Current Pharmaceutical Design Pharmacological and Non-pharmacological Therapies of Cognitive Impairment in Multiple Sclerosis
Current Neuropharmacology Matrix Metalloproteinases in Vascular Disease - A Potential Therapeutic Target?
Current Vascular Pharmacology Commentary ( Two Hits with One Shot – A Possibility of Simultaneous Targeting Motor Neuron Loss and Depression in ALS by Upregulating ADAR2 )
CNS & Neurological Disorders - Drug Targets In Silico Validation and Structure Activity Relationship Study of a Series of Pyridine-3-carbohydrazide Derivatives as Potential Anticonvulsants in Generalized and Partial Seizures
Central Nervous System Agents in Medicinal Chemistry Role of Polyunsaturated Fatty Acids and Fatty Acid Binding Protein in the Pathogenesis of Schizophrenia
Current Pharmaceutical Design Determination of Cr(VI) by Dispersive Liquid-Liquid Microextraction and Dried-Droplet Laser Ablation ICP-MS
Current Analytical Chemistry Different Factors Influence Recanalisation Rate After Coiling in Ruptured and Unruptured Intracranial Aneurysms
CNS & Neurological Disorders - Drug Targets